Profile data is unavailable for this security.
About the company
Antengene Corp Ltd is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.
- Revenue in HKD (TTM)61.95m
- Net income in HKD-585.05m
- Incorporated2018
- Employees178.00
- LocationAntengene Corp LtdUgland HousePO Box 309SHANGHAI KY1-1104ChinaCHN
- Websitehttps://www.antengene.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Health Group Inc | 27.28m | -62.63m | 126.41m | 41.00 | -- | 1.24 | -- | 4.63 | -0.0629 | -0.0629 | 0.0274 | 0.1023 | 0.1547 | -- | 0.2559 | 649,577.50 | -35.50 | 6.84 | -47.26 | 9.52 | 42.55 | 74.98 | -229.55 | 19.19 | -- | -1,310.95 | -- | 0.00 | 63.67 | -18.51 | -267.82 | -- | 30.37 | -- |
| Sirnaomics Ltd | 0.00 | -637.18m | 258.53m | 90.00 | -- | 136.02 | -- | -- | -8.39 | -8.39 | 0.00 | 0.0217 | 0.00 | -- | -- | 0.00 | -110.32 | -- | -136.58 | -- | -- | -- | -- | -- | -- | -3.25 | -- | -- | -- | -- | 10.88 | -- | -- | -- |
| Clover Biopharmaceuticals Ltd | 31.93m | -977.01m | 294.43m | 323.00 | -- | -- | -- | 9.22 | -0.7834 | -0.7834 | 0.0256 | -0.7094 | 0.0119 | 0.014 | 98.80 | 82,501.76 | -36.27 | -- | -405.86 | -- | 54.86 | -- | -3,060.03 | -- | 0.4426 | -- | -- | -- | -- | -- | 94.35 | -- | -- | -- |
| Antengene Corp Ltd | 61.95m | -585.05m | 384.69m | 178.00 | -- | 0.3504 | -- | 6.21 | -0.9485 | -0.9485 | 0.1004 | 1.63 | 0.035 | 0.6597 | 1.57 | 308,194.90 | -33.06 | -53.57 | -37.16 | -58.94 | 84.84 | -- | -944.43 | -1,987.01 | 5.66 | -23.74 | 0.1663 | -- | -57.97 | -- | 3.38 | -- | 202.03 | -- |
| Kintor Pharmaceutical Ltd | 0.00 | -1.02bn | 420.65m | 175.00 | -- | 0.9723 | -- | -- | -2.37 | -2.37 | 0.00 | 0.9668 | 0.00 | 0.1411 | -- | 0.00 | -70.41 | -50.15 | -87.57 | -58.43 | -- | -27.62 | -- | -10,511.41 | 1.56 | -111.48 | 0.3788 | -- | -- | -- | -11.15 | -- | -32.49 | -- |
| HighTide Therapeutics Inc | 0.00 | -663.47m | 442.70m | 66.00 | -- | 0.6708 | -- | -- | -1.43 | -1.43 | 0.00 | 1.28 | 0.00 | -- | -- | 0.00 | -87.01 | -- | -118.34 | -- | -- | -- | -- | -- | -- | -- | 0.0404 | -- | -- | -- | -393.76 | -- | -- | -- |
| JW (Cayman) Therapeutics Co Ltd | 191.06m | -693.68m | 539.72m | 323.00 | -- | 0.3274 | -- | 2.82 | -1.68 | -1.68 | 0.4632 | 3.97 | 0.0747 | 1.87 | 11.48 | 480,060.70 | -27.11 | -39.77 | -31.71 | -44.00 | 50.40 | -- | -363.06 | -1,316.81 | 2.76 | -- | 0.2043 | -- | 19.32 | -- | 9.23 | -- | -19.87 | -- |
| Brii Biosciences Ltd | 0.00 | -293.28m | 745.21m | 95.00 | -- | 0.2357 | -- | -- | -0.4019 | -0.4019 | 0.00 | 4.33 | 0.00 | -- | -- | 0.00 | -8.89 | -- | -9.01 | -- | -- | -- | -- | -- | -- | -- | 0.007 | -- | -98.80 | -- | 63.90 | -- | -- | -- |
| Genor Biopharma Holdings Ltd | 15.99m | -580.61m | 857.97m | 28.00 | -- | 0.7229 | -- | 53.67 | -1.14 | -1.14 | 0.0315 | 2.28 | 0.0093 | 0.0178 | 0.2277 | 153,724.00 | -33.87 | -55.46 | -39.06 | -63.73 | 97.59 | 66.56 | -3,638.27 | -14,819.18 | 5.73 | -- | 0.003 | -- | -100.00 | -- | 7.65 | -- | -48.85 | -- |
| Sunho Biologics Inc | -100.00bn | -118.54m | 908.67m | -- | -- | 1.50 | -- | -- | -0.88 | -0.88 | -- | 3.86 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.77 | -4,626.67 | 0.0516 | -- | -- | -- | -155.25 | -- | -- | -- |
Data as of Sep 24 2024. Currency figures normalised to Antengene Corp Ltd's reporting currency: Hong Kong Dollar HKD
2.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research (Hong Kong) Ltd.as of 30 Jun 2024 | 8.90m | 1.32% |
| Zeal Asset Management Ltd.as of 31 Dec 2023 | 6.32m | 0.94% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.82m | 0.27% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 1.51m | 0.22% |
| Dimensional Fund Advisors LPas of 03 Jul 2024 | 677.50k | 0.10% |
| Dimensional Fund Advisors Ltd.as of 31 May 2024 | 60.23k | 0.01% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 17.50k | 0.00% |
| American Century Investment Management, Inc.as of 30 Jun 2024 | 12.50k | 0.00% |
| DFA Australia Ltd.as of 30 Jun 2024 | 2.50k | 0.00% |
More ▼
Data from 31 Dec 2023 - 06 Aug 2024Source: FactSet Research Systems Inc.
